ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2381

Serum Level of IL-33 and Soluble ST2 and Their Association with Disease Activity in Patients with Behcet’s Disease

Dae-Jun Kim1, Jae-Ho Lee1, Ji Hyeon Ju1, Sung-Hwan Park2, Ho-Youn Kim1 and Seung-Ki Kwok1, 1Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 2Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Interleukin-33 (IL-33) is a new member of the IL-1 family of cytokines which signals via receptor, ST2(IL-33R), and has an important role in Neutrophil migrations, Th2 responses and mast cell responses. This study aims to measure the serum levels of IL-33 and soluble ST2 (sST2) in patients with Behcet’s disease (BD) and to examine their association with disease activity.

Methods: Fifty three BD patients were evaluated for disease activity, determined by BDCAF, IBDDAM, ESR/CRP levels. IL-33 and sST2 were measured by sandwich ELISA in the 53 BD serum samples and compared with 31 age- and sex-matched healthy controls. The cutaneous expressions of IL-33 and sST2 in BD patients with erythema nodosum(EN) or EN-like lesion was compared with normal control skin tissues by immunohistochemical stains

Results:

Serum IL-33 level was significantly higher in active BD patients [ 594.48 pg/ml] compared with normal controls [ 224.23 pg/ml] (P<0.05), and soluble ST2(sST2) level was also significantly higher in active BD patients [99.01 pg/ml] compared with normal controls [23.56 pg/ml]. The tissue expressions of IL-33 and sST2, shown by immunohistochemistry, were higher in BD compared with the controls. Serum sST2 level correlated significantly with BDCAF, IBDDAM, ESR and CRP. Multiple linear regression showed that both serum CRP and serum sST2 were independent predictive factor for IBDDAM (regression coefficient: 0.519 ; P = 0.000, regression coefficient: 0.300 ; P = 0.016, respectively)

Conclusion:

These results suggest that IL-33 and sST2 area increased in Behcet’s disease and The level of  sST2 are correlated with Behcet’s disease activity index (IBDDAM) and acute phase reactant (ESR, CRP) and also a independent predictive factor of IBDDAM, suggesting a potential role of sST2 as a surrogate marker of disease activity of BD.


Disclosure:

D. J. Kim,
None;

J. H. Lee,
None;

J. H. Ju,
None;

S. H. Park,
None;

H. Y. Kim,
None;

S. K. Kwok,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-level-of-il-33-and-soluble-st2-and-their-association-with-disease-activity-in-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology